Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL.

No abstract

No abstract

Key Points Topical resiquimod is a safe, effective therapy for early-stage CTCL that can clear both treated and untreated skin lesions. Responding patients had T-cell recruitment into skin, enhanced T-cell effector functions, and eradication of the malignant T-cell clones.